Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens.
Immunotherapy
; 12(8): 571-576, 2020 06.
Article
in English
| MEDLINE | ID: covidwho-245635
ABSTRACT
Aim:
There is a critical need for effective therapies that are immediately available to control the spread of COVID-19 disease. Material &methods:
Gamunex®-C and Flebogamma® DIF (Grifols) intravenous immunoglobulin (IVIG) products were tested using ELISA techniques for antibodies against several antigens of human common betacoronaviruses that may crossreact with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus.Results:
Both IVIGs showed consistent reactivity to components of the tested viruses. Positive crossreactivity was seen in SARS-CoV, middle east respiratory syndrome-CoV and SARS-CoV-2. For SARS-CoV-2, positive reactivity was observed at IVIG concentrations ranging from 100 µg/ml with Gamunex-C to 1 mg/ml with Flebogamma 5% DIF.Conclusion:
Gamunex-C and Flebogamma DIF contain antibodies reacting against SARS-CoV-2 antigens. Studies to confirm the utility of IVIG preparations for COVID-19 management may be warranted.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Immunoglobulins, Intravenous
/
Coronavirus Infections
/
Severe acute respiratory syndrome-related coronavirus
/
Betacoronavirus
/
Antigens, Viral
Type of study:
Randomized controlled trials
Limits:
Humans
Language:
English
Journal:
Immunotherapy
Journal subject:
Allergy and Immunology
/
Therapeutics
Year:
2020
Document Type:
Article
Affiliation country:
Imt-2020-0095
Similar
MEDLINE
...
LILACS
LIS